US 11,957,893 B2
Minimally invasive implantable neurostimulation system
Brad C. Tischendorf, Minneapolis, MN (US); John E. Kast, Hugo, MN (US); Thomas P. Miltich, Otsego, MN (US); Gordon O. Munns, Stacy, MN (US); Randy S. Roles, Elk River, MN (US); Craig L. Schmidt, Eagan, MN (US); Joseph J. Viavattine, Vadnais Heights, MN (US); Christian S. Nielsen, River Falls, WI (US); Prabhakar A. Tamirisa, Brooklyn Park, MN (US); Anthony M. Chasensky, St. Paul, MN (US); Markus W. Reiterer, Plymouth, MN (US); Chris J. Paidosh, Minneapolis, MN (US); Reginald D. Robinson, Plymouth, MN (US); Bernard Q. Li, Plymouth, MN (US); Erik R. Scott, Maple Grove, MN (US); Phillip C. Falkner, Minneapolis, MN (US); Xuan K. Wei, Minnetonka, MN (US); Eric H. Bonde, Minnetonka, MN (US); David A. Dinsmoor, St. Paul, MN (US); Duane L. Bourget, Minneapolis, MN (US); Forrest C M Pape, New Brighton, MN (US); Gabriela C. Molnar, Blaine, MN (US); Joel A. Anderson, Brooklyn Park, MN (US); Michael J. Ebert, Fridley, MN (US); Richard T. Stone, Minneapolis, MN (US); Shawn C. Kelley, Shoreview, MN (US); Stephen J. Roddy, Minneapolis, MN (US); Timothy J. Denison, Minneapolis, MN (US); and Todd V. Smith, Shoreview, MN (US)
Assigned to Medtronic, Inc., Minneapolis, MN (US)
Filed by Medtronic, Inc., Minneapolis, MN (US)
Filed on Aug. 25, 2020, as Appl. No. 16/947,944.
Application 16/947,944 is a continuation of application No. 15/900,083, filed on Feb. 20, 2018, granted, now 10,792,488.
Application 15/900,083 is a continuation of application No. 14/098,621, filed on Dec. 6, 2013, granted, now 9,931,107, issued on Apr. 3, 2018.
Claims priority of provisional application 61/777,824, filed on Mar. 12, 2013.
Claims priority of provisional application 61/777,787, filed on Mar. 12, 2013.
Claims priority of provisional application 61/777,804, filed on Mar. 12, 2013.
Claims priority of provisional application 61/777,949, filed on Mar. 12, 2013.
Claims priority of provisional application 61/777,838, filed on Mar. 12, 2013.
Claims priority of provisional application 61/734,429, filed on Dec. 7, 2012.
Claims priority of provisional application 61/734,446, filed on Dec. 7, 2012.
Claims priority of provisional application 61/734,425, filed on Dec. 7, 2012.
Claims priority of provisional application 61/734,436, filed on Dec. 7, 2012.
Prior Publication US 2020/0376255 A1, Dec. 3, 2020
This patent is subject to a terminal disclaimer.
Int. Cl. A61N 1/02 (2006.01); A61B 17/00 (2006.01); A61N 1/05 (2006.01); A61N 1/36 (2006.01); A61N 1/372 (2006.01); A61N 1/375 (2006.01); A61N 1/378 (2006.01)
CPC A61N 1/02 (2013.01) [A61B 17/00234 (2013.01); A61N 1/05 (2013.01); A61N 1/0551 (2013.01); A61N 1/36007 (2013.01); A61N 1/3605 (2013.01); A61N 1/36057 (2013.01); A61N 1/36067 (2013.01); A61N 1/36071 (2013.01); A61N 1/36139 (2013.01); A61N 1/37205 (2013.01); A61N 1/37223 (2013.01); A61N 1/37235 (2013.01); A61N 1/37247 (2013.01); A61N 1/3727 (2013.01); A61N 1/3754 (2013.01); A61N 1/3756 (2013.01); A61N 1/3787 (2013.01); A61N 1/36021 (2013.01); A61N 1/36053 (2013.01); A61N 1/37211 (2013.01); A61N 1/37518 (2017.08); F04C 2270/0421 (2013.01)] 16 Claims
OG exemplary drawing
 
1. A minimally invasive implantable tibial nerve stimulation device, comprising:
an enclosure constructed of at least one of a biocompatible titanium or stainless steel,
the enclosure formed as a single tube having a circular cross-section with an overall length of less than about thirty millimeters and a total volume of less than about one cubic centimeter to enable minimally invasive implantation of the enclosure within a body of a patient;
a power supply;
device electronics within the enclosure including:
a pulse generating circuit;
a control unit; and
memory, the memory including memory-readable instructions that when executed by the control unit cause the pulse generating circuit of the minimally invasive implantable tibial nerve stimulation device to deliver a nerve stimulation therapy to the tibial nerve of the patient,
wherein operation of the minimally invasive implantable tibial nerve stimulation device is selectively adjustable via an external magnetic field; and
a telemetry module within the enclosure,
the telemetry module configured to enable communication with at least one external programming device, wherein communication with the external programming device enables receipt of a command to adjust an intensity or strength of the therapy up or down,
wherein communication with the device electronics is confirmable by the external programming device; and
an insulative outer coating at least partially surrounding the hermetically sealed enclosure and configured to protect the enclosure and to reduce patient discomfort; and
an insulated lead including:
a proximal end configured to be connected to an electrically insulated, sealed header located on one end of the enclosure, and
a distal end including two or more electrodes in electrical communication with the device electronics, the two or more electrodes spaced apart from one another and constructed of at least one of a conductive platinum or platinum iridium material,
wherein the lead is configured to be positioned to the tibial nerve of a patient for the delivery of the nerve stimulation therapy to the tibial nerve of the patient as a treatment for symptoms related to urinary incontinence or an overactive bladder.